NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vaxinano

Vaxinano

Private
LoosHealthcare & Life Scienceshttps://www.vaxinano.com/

Last Round

Seed

Oct 29, 2024

Total Funding Raised

$7.09M

Company Overview

Vaxinano is a biotechnology company that develops prophylactic and therapeutic nasal vaccines intended to treat infectious diseases for human and animal health.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

nanoparticle vaccinenasal vaccineneedle-free vaccinedrug delivery platformadjuvant-free vaccineveterinary vaccinebiotech licensingcontract research organizationCROvaccine R&Dmucosal vaccinenanotech drug deliverycold-chain freenext-gen vaccinesnasal spray vaccine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vaxinano Comparables

Compare Vaxinano with similar companies based on industry and business-model similarity.

Vaxinano comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lovaltech
80%
POP Biotechnologies, Inc.
78%
Xanadu Bio
78%

Vaxinano Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 29, 2024
GrantJun 1, 2020
SeedJun 22, 2017

Key People

Founding team and executive leadership

Didier Betbeder

CEO And CSO, President CSO Vaxinano

Executive Team

Jonathan Stauber

Chief Executive Officer

Executive Team

Vaxinano Investors

Notable investors and investment history

Vaxinano investors
InvestorRounds
Agence Nationale de la RechercheGrant
BpifranceSeed
WiSeedSeed
TCD CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 29, 2024

    $6.46M raised from Finorpa and Nord France Amorquage.

Vaxinano Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vaxinano Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vaxinano's valuation, stock price, and market status.

Firmographic Details

HeadquartersLoos
Employee Range13
Year Founded2016
Last FundingOct 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.